GGrantIndex
← Leaderboards

Robert H. Bartlett

University Of Michigan At Ann Arbor

$24,314,191
Attributed
$28,651,396
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.4M · FY200523
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$28,651,396 · 12

By mechanism

R01$25,213,978 · 7
R42$1,675,558 · 1
R21$835,768 · 2
R34$697,500 · 1
R41$228,592 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Nitric Oxide

Research focus

Nitric OxideDevicesThrombosisLaboratoriesClinical TrialsLungSurfaceSheepAnimal ModelTechnologyGrantBloodPreventExtracorporeal CirculationChronicClinical ApplicationLung TransplantationDesignLifeGasesBlood CirculationAnimalsAnticoagulationCoagulation Process

Grant awards (50)

Research Supplement to Promote Diversity Supplement for the ECMO without Anticoagulation$43,232
R01 · FY2023 · HL · contact PI
Low Cost Electrochemical Gas Phase Nitric Oxide Generator for Biomedical Applications$865,106
R42 · FY2022 · HL
Prolonged Normothermic Ex vivo Heart Perfusion (NEVHP)$776,002
R01 · FY2022 · HL · contact PI
ECMO without Anticoagulation$764,547
R01 · FY2022 · HL · contact PI
ECMO without Anticoagulation$747,387
R01 · FY2021 · HL · contact PI
Low Cost Electrochemical Gas Phase Nitric Oxide Generator for Biomedical Applications$602,645
R42 · FY2021 · HL
ECPR After Prolonged Cardiac Arrest: Targeting Mechanisms of the No-Reflow$751,384
R01 · FY2020 · HL
ECPR After Prolonged Cardiac Arrest: Targeting Mechanisms of the No-Reflow$756,708
R01 · FY2019 · HL
The Cause of Systemic Inflammatory Response during Cardiopulmonary Bypass and Prevention by Nitric Oxide$674,320
R01 · FY2019 · HL · contact PI
Low Cost Electrochemical Gas Phase Nitric Oxide Generator for Biomedical Applications$207,807
R42 · FY2019 · HL
ECPR After Prolonged Cardiac Arrest: Targeting Mechanisms of the No-Reflow$784,250
R01 · FY2018 · HL
Bactericidal, Nonthrombogenic Intravascular Catheters$697,474
R01 · FY2018 · HL · contact PI
ECPR After Prolonged Cardiac Arrest: Targeting Mechanisms of the No-Reflow$774,905
R01 · FY2017 · HL
Bactericidal, Nonthrombogenic Intravascular Catheters$717,819
R01 · FY2017 · HL · contact PI
Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest (EROCA) Trial Planning Grant$348,750
R34 · FY2017 · HL
Electrochemical Generation of Nitric Oxide for Gas Phase Biomedical Applications$187,522
R21 · FY2017 · HD · contact PI
Bactericidal, Nonthrombogenic Intravascular Catheters$689,919
R01 · FY2016 · HL · contact PI
Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest (EROCA) Trial Planning Grant$348,750
R34 · FY2016 · HL
Electrochemical Generation of Nitric Oxide for Gas Phase Biomedical Applications$226,453
R21 · FY2016 · HD · contact PI
Bactericidal, Nonthrombogenic Intravascular Catheters$714,919
R01 · FY2015 · HL · contact PI
Combined Nitric Oxide Release and Argatroban for Thromboresistant Coatings$188,543
R21 · FY2014 · EB · contact PI
Pediatric Implantable Artificial Lung$484,382
R01 · FY2013 · HD · contact PI
Combined Nitric Oxide Release and Argatroban for Thromboresistant Coatings$233,250
R21 · FY2013 · EB · contact PI
Mini ECMO Life Support System$228,592
R41 · FY2013 · HD · contact PI
Pediatric Implantable Artificial Lung$527,981
R01 · FY2012 · HD · contact PI
Development of a Total Artificial Lung$997,603
R01 · FY2011 · HL · contact PI
Extracorporeal Circulation Without Anticoagulation$557,534
R01 · FY2011 · HD · contact PI
Development of a Total Artificial Lung$982,500
R01 · FY2010 · HL · contact PI
Extracorporeal Circulation Without Anticoagulation$581,838
R01 · FY2010 · HD · contact PI
Development of a Total Artificial Lung$55,215
R01 · FY2010 · HL · contact PI
Development of a Total Artificial Lung$1,080,201
R01 · FY2009 · HL · contact PI
Extracorporeal Circulation Without Anticoagulation$592,257
R01 · FY2009 · HD · contact PI
Development of a Total Artificial Lung$21,717
R01 · FY2009 · HL · contact PI
Development of a Total Artificial Lung$964,147
R01 · FY2008 · HL · contact PI
Extracorporeal Circulation Without Anticoagulation$590,614
R01 · FY2008 · HD · contact PI
Development of a Total Artificial Lung$26,540
R01 · FY2008 · HL · contact PI
Development of a Total Artificial Lung$821,764
R01 · FY2007 · HL · contact PI
Development of a Total Artificial Lung$1,222,026
R01 · FY2006 · HL · contact PI
Extracorporeal Circulation Without Anticoagulation$550,438
R01 · FY2006 · HD · contact PI
Development of a Total Artificial Lung$1,126,972
R01 · FY2005 · HL
Extracorporeal Circulation Without Anticoagulation$581,665
R01 · FY2005 · HD
Development of a Total Artificial Lung$978,673
R01 · FY2004 · HL
Extracorporeal Circulation Without Anticoagulation$591,126
R01 · FY2004 · HD
Development of a Total Artificial Lung$6,701
R01 · FY2004 · HL
Development of a Total Artificial Lung$873,049
R01 · FY2003 · HL
Development of a Total Artificial Lung$37,732
R01 · FY2003 · HL
Development of a Total Artificial Lung$884,809
R01 · FY2002 · HL
ECLS IN MULTIPLE ORGAN FAILURE$409,003
R01 · FY2002 · HD
ECLS IN MULTIPLE ORGAN FAILURE$394,315
R01 · FY2001 · HD
ECLS IN MULTIPLE ORGAN FAILURE$380,310
R01 · FY2000 · HD